Frazier Life Sciences Management, L.P.
Top Portfolio Positions
36 positions ·
$3,872,946,698 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| MIRM |
Mirum Pharmaceuticals, Inc.
Healthcare
|
7,679,684 | $709,449,207 | 18.32% | |
| NAMS |
NewAmsterdam Pharma Co N.V.
Healthcare
|
16,943,774 | $542,370,205 | 14.00% | |
| ERAS |
Erasca, Inc.
Healthcare
|
24,675,188 | $399,244,541 | 10.31% | |
| BBIO |
BridgeBio Pharma, Inc.
Healthcare
|
3,448,139 | $256,058,802 | 6.61% | |
| ARQT |
Arcutis Biotherapeutics, Inc.
Healthcare
|
9,874,511 | $232,643,479 | 6.01% | |
| MBX |
MBX Biosciences, Inc.
Healthcare
|
6,652,013 | $198,562,588 | 5.13% | |
| PHAT |
Phathom Pharmaceuticals, Inc.
Healthcare
|
12,466,489 | $138,502,692 | 3.58% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
4,567,274 | $136,333,128 | 3.52% | |
| KRYS |
Krystal Biotech, Inc.
Healthcare
|
481,307 | $124,331,224 | 3.21% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
9,939,547 | $118,578,795 | 3.06% |
Portfolio Trend
17 quarters · across all stocks
Holdings in MBX
Shares Held
Position Value (USD)
7 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $198,562,588 | 6,652,013 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $209,804,490 | 6,652,013 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $116,410,227 | 6,652,013 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $68,292,809 | 5,985,347 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $44,171,860 | 5,985,347 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $110,309,945 | 5,985,347 | Shares | Sole | 2025-02-18 | |
| 2024-09-30 | $155,499,315 | 5,985,347 | Shares | Sole | 2024-11-15 | |
| No 13F history on record for this holder in this stock. | ||||||